Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
July 31, 2025 9:00 AM
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $678.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
